Pam shares some thoughts on working with the team at the Arthritis Center and the importance of research to her and others.
Dr. Rebecca Manno, Director of the Johns Hopkins Rheumatology Exercise Center answers the question; “My doctor told me to lose weight but I can’t exercise because my knees hurt, what can I do?”
Key Points Sjögren’s syndrome can cause inflammation damaging the glands that secrete fluids such as salivary glands. This can lead to cavities through the mouth, severe oral dryness, difficulty eating, and even tooth loss Arthritis can affect the temporomandibular joint (TMJ) that opens and closes the mouth sometimes making it painful to open and close […]
Julie shares her experiences with the Arthritis Center team and the importance of participating in research.
Key Points The Johns Hopkins Arthritis Center conducted a study to determine the presence of gum disease in patients who have Rheumatoid Arthritis (RA). Oral health exams were performed on patients who have RA and healthy volunteers for comparison. Data was collected from 100 RA patients and 40 healthy volunteers. 70% of the RA patients […]
A recent study by the Johns Hopkins Arthritis Center reveals yoga holds positive results for arthritis sufferers in terms of both mind and body.
RAVE Mobile provides interactive, point-of-care, practice improvement tools for rheumatologists and other clinicians.
Initial combination therapy has been shown to be superior to step-up combination therapy in groups of RA patients; however, these findings are difficult to reconcile with the observation that many RA patients will have complete remission of disease on methotrexate alone. Practice patterns tend to emphasize initial treatment with methotrexate monotherapy, followed by the addition of other agents in combination for those with inadequate responses.
Antibodies against citrullinated proteins have emerged as powerful diagnostic and prognostic tools in RA that may contribute to the initiation phases of the disease. The enzymes that catalyze the citrullination process, known as peptidyl argenine deiminases (or PADs), may also be involved in the initiation and propagation steps of the RA disease process. Additionally, autoimmunity to these catalysts may identify a subset of RA patients with unique disease phenotypes.
The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis. However, it has not demonstrated efficacy for the treatment of psoriatic arthritis and, in one study, was associated with worsening of arthritis symptoms. Only a minority of individuals with psoriasis have a concomitant inflammatory arthritis, making therapy with efalizumab an option for the treatment of a large number of psoriasis patients who have no articular involvement.